Biomarkers in AL Amyloidosis

por Fotiou, Despina, Theodorakakou, Foteini, Kastritis, Efstathios
Publicado 2021

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia

por Fotiou, Despina, Theodorakakou, Foteini, Kastritis, Efstathios
Publicado 2022

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia

por Gavriatopoulou, Maria, Kastritis, Efstathios, Dimopoulos, Meletios Athanasios
Publicado 2017

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management

por Fotiou, Despina, Dimopoulos, Meletios Athanasios, Kastritis, Efstathios
Publicado 2020

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

por Theodorakakou, Foteini, Dimopoulos, Meletios A., Kastritis, Efstathios
Publicado 2021

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma

por Fotiou, Despina, Dimopoulos, Meletios Athanasios, Kastritis, Efstathios
Publicado 2022

Monoclonal Gammopathy of Thrombotic Significance

por Gkalea, Vasiliki, Fotiou, Despina, Dimopoulos, Meletios Athanasios, Kastritis, Efstathios
Publicado 2023

How I treat rituximab refractory patients with WM

por Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Kastritis, Efstathios, Dimopoulos, Meletios Athanasios
Publicado 2018

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment

por Fotiou, Despina, Skalioti, Chrysanthi, Liapis, George, Marinaki, Smaragdi, Kastritis, Efstathios
Publicado 2021

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

por Terpos, Evangelos, Kanellias, Nikolaos, Christoulas, Dimitrios, Kastritis, Efstathios, Dimopoulos, Meletios A
Publicado 2013

Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches

por van de Donk, Niels W. C. J., Kastritis, Efstathios, Gay, Francesca
Publicado 2020

Exercise-Induced Changes in Tumor Growth via Tumor Immunity

por Spiliopoulou, Polyxeni, Gavriatopoulou, Maria, Kastritis, Efstathios, Dimopoulos, Meletios Athanasios, Terzis, Gerasimos
Publicado 2021

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia

por Papanota, Aristea-Maria, Ntanasis-Stathopoulos, Ioannis, Kastritis, Efstathios, Dimopoulos, Meletios A, Gavriatopoulou, Maria
Publicado 2019

Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology

por Galani, Aikaterini, Alygizakis, Nikiforos, Aalizadeh, Reza, Kastritis, Efstathios, Dimopoulos, Meletios-Athanasios, Thomaidis, Nikolaos S.
Publicado 2021

How I treat elderly patients with plasma cell dyscrasias

por Gavriatopoulou, Maria, Fotiou, Despoina, Ntanasis-Stathopoulos, Ioannis, Kastritis, Efstathios, Terpos, Evangelos, Dimopoulos, Meletios Athanasios
Publicado 2018

Efficacy of Panobinostat for the Treatment of Multiple Myeloma

por Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Kastritis, Efstathios, Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios Athanasios
Publicado 2020

Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes

por Kastritis, Efstathios, Kitas, George D., Vassilopoulos, Dimitrios, Giannopoulos, Georgios, Dimopoulos, Meletios A., Sfikakis, Petros P.
Publicado 2020

Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients

por Melea, Pelagia I., Melakopoulos, Ioannis, Kastritis, Efstathios, Tesseromatis, Christina, Margaritis, Vasileios, Dimopoulos, Meletios A., Terpos, Evangelos
Publicado 2014

PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGE...

por Wechalekar, Ashutosh, Palladini, Giovanni, Molina, Maria Angelica, Kastritis, Efstathios, Ianus, Juliana, Catini, Julia, Quarta, C Cristina, Liedtke, Michaela
Publicado 2023

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent

por Papanagnou, Eleni-Dimitra, Terpos, Evangelos, Kastritis, Efstathios, Papassideri, Issidora S., Tsitsilonis, Ourania E., Dimopoulos, Meletios A., Trougakos, Ioannis P.
Publicado 2018